Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Monthly Archives: September 2015

HHS Announces $685 Million to Support Clinicians Delivering Patient-Centered Care; Two NJ Orgs Receive Funding

 Washington, DC, September 30, 2015 ― Health and Human Services Secretary Sylvia M. Burwell yesterday announced $685 million in awards to 39 national and regional health care networks and supporting organizations — including two in New Jersey — to help equip more than 140,000 clinicians with the tools and support needed to improve quality of care, increase patients’ access to information, and reduce costs.

The Transforming Clinical Practice Initiative is one of the largest federal investments designed to support doctors and other clinicians in all 50 states through collaborative and peer-based learning networks. Continue reading

HINJ Launches ‘Value of Medical Innovation’ Portal; Focuses on Saving Lives — And Saving Money

VMINew Brunswick, NJ, September 29, 2015 ― The HealthCare Institute of New Jersey (HINJ) has updated its online portal at HINJ.org to present Value of Medical Innovation, a fact-driven, consumer-friendly digital library that delves into the myriad benefits of medical innovation, which saves lives — and saves money.

HINJ’s Value of Medical Innovation presents statistics from a number of resources, including the U.S. government, the Advanced Medical Technology Association (AdvaMed), the Biotechnology Organization (BIO), the Pharmaceutical Research and Manufacturers of America (PhRMA) and various medical research organizations. Continue reading

PhRMA Names Stephen J. Ubl as Next President and CEO; Succeeds John Castellani

Steve UblWashington, DC, September 29, 2015 ― The Pharmaceutical Research and Manufacturers of America (PhRMA) Board of Directors on Friday announced that Stephen J. Ubl will be the next president and chief executive officer (CEO) of the association.

Ubl joins PhRMA after more than ten years as the president and CEO of the Advanced Medical Technology Association (AdvaMed), the world’s largest medical technology association.

He succeeds John J. Castellani who announced earlier this year that he will be retiring at the end of the year. Continue reading

Event: Lt. Governor Guadagno to Speak at Innovation NJ’s 5th Anniverary October 1

Kim Guadagno high res

Trenton, NJ, September 28, 2015 ― New Jersey Lt. Governor Kim Guadagno will address attendees at Innovation New Jersey’s (INJ) 5th anniversary event, which will be held at AT&T’s Corporate Campus in Bedminster Township on October 1 from 8:00 a.m. to 12:30 p.m.

The event, which will showcase New Jersey as the “Innovation State,” will be co-hosted by the New Jersey Policy Research Organization Foundation (NJPRO), the New Jersey Business & Industry Association (NJBIA) and the HealthCare Institute of New Jersey (HINJ).

Dr. Tony Boccanfuso, President, University-Industry Demonstration Partnership, also will keynote.

Continue reading

Report: Eliminating Hepatitis C Could Reduce Future U.S. Health Care Spending by $115 Billion Over Next Decade

Washington, DC, September 27, 2015 ― The Pharmaceutical Research and Manufacturers of America (PhRMA) reports that a new study by Milliman on the clinical burden of hepatitis C projects that the incremental cost of hepatitis C to the U.S. health care system is projected to be $115 billion over the next decade.

The report estimates that, in the absence of a cure for hepatitis C, more than 350,000 patients would be living with advanced stages of the disease — including 100,000 more with cirrhosis of the liver and 250,000 more patients with end stage liver disease — by 2025.

According to the report, government programs would bear a significant share of this burden. The Medicare program would spend an additional $30.4 billion, while Medicaid would incur additional spending of $21.5 billion. Continue reading

CMS Proposes New Medicare Clinical Diagnostic Laboratory Tests Fee Schedule

Washington, DC, September 26, 2015 ― The Centers for Medicare & Medicaid Services (CMS) has announced its next step in implementing the Protecting Access to Medicare Act of 2014 (PAMA), requiring clinical laboratories to report on private insurance payment amounts and volumes for lab tests.

This data will be used to determine Medicare’s payment for lab tests beginning January 1, 2017.

“Modernizing Medicare’s payment for clinical lab tests is another example of our commitment to spending health care dollars more wisely,” said CMS Deputy Administrator and Chief Medical Officer, Patrick Conway, M.D., M.S. “This demonstrates CMS’ dedication to collaborating with private payors to improve the delivery system.” Continue reading

Poll Finds Majority of Voters Oppose Government Price-Setting for Prescription Drugs

Washington, DC, September 25, 2015 ― A majority of voters (51 percent compared to 36 percent) oppose allowing the federal government to set the price of prescription medicines, a new poll found.

The Morning Consult poll of 2,042 registered voters found most voters (49 percent compared to 23 percent) believe the private sector does a better job negotiating prescription drug prices than the government.

Majorities say “patients access to medicines would be limited” (61 percent) and “fewer new medicines would be developed” (65 percent) if the government set the price of prescription medicines.” Continue reading

Rutgers Cancer Institute of NJ Awarded $400K for Research to Help Breast Cancer Patients with a Challenging Decision

Rutgers CINJ LogoNew Brunswick, NJ, September 25, 2015 ― Rutgers Cancer Institute of New Jersey surgical oncologist Laurie J. Kirstein, MD, FACS, and Associate Director for Cancer Prevention, Control and Population Science Sharon L. Manne, PhD, have been awarded a $404,089 grant (R21CA187643) from the National Cancer Institute to explore the decision making process women with non-hereditary breast cancer undergo when considering the removal of a healthy breast.

The aim is to develop a web-based tool to aid them in this process.

Removal of a healthy breast (contralateral prophylactic mastectomy or CPM) has risen five-fold in the past 15 years in women diagnosed with breast cancer in one breast with no family history (Stucky, Gray, Wasif, et al., Annals of Surgical Oncology, 2010; 17: 330-337).  Continue reading

Express Scripts: The Cost of Not Taking Medications as Prescribed Is $330 Billion

Washington, DC, September 24, 2015 ― Elizabeth O’Brien reports in MarketWatch that pharmacy benefit manager Express Scripts’ 2014 Drug Trend Report found that prescription non-adherence costs the US roughly $330 billion a year in unnecessary medical complications.  The report breaks down adherence by ailment, and the numbers are startling.

While people sometimes scrimp on medications to save money, this can lead to bigger health problems with bigger price tags, like a trip to the emergency room.

The Express Scripts 2014 Drug Trend Report breaks down adherence by ailment, and the numbers are startling. Continue reading

PhRMA Says Hillary Clinton’s Drug-Pricing Plan Would Turn Back the Clock on Medical Innovation

PhRMA jpgWashington, DC, September 23, 2015 ― The Pharmaceutical Research and Manufacturers of America (PhRMA) released a statement yesterday regarding former Secretary of State Hillary Rodham Clinton’s drug-pricing plan, which she unveiled.

In the statement, PhRMA President and CEO John J. Castellani said:

“Researchers and scientists across the biopharmaceutical industry have dedicated their lives to the search for new treatments and cures for patients.  They do this against seemingly insurmountable odds, knowing that despite years of work on potential medicines nine out of ten will fail during clinical trials and the process will start over.

“This persistence and dedication to patients has resulted in tremendous advances against some of life’s biggest enemies, including cancer, hepatitis c, heart disease and other terrible diseases. Continue reading